Search

PDIA4 Inhibitors Treat Diabetes, Preserve Beta Cells

USPTO has granted Patent US12605353B2 to Academia Sinica, covering disulfide-isomerase A4 (PDIA4) inhibitors for inhibiting pancreatic beta-cell pathogenesis and treating diabetes. The patent discloses drug candidates with IC50 values ranging from 4 micrometers to 300 nanomolars that augment insulin secretion from pancreatic beta-cells. Pharmaceutical companies developing diabetes or metabolic disease therapeutics should monitor this IP landscape for potential licensing, freedom-to-operate, or R&D pathway considerations.

Bipartite molecules treating neurodegenerative diseases

USPTO granted Patent US12590130B2 to Academia Sinica for bipartite molecules comprising a peptide affinity moiety and charged moieties for treating neurodegenerative diseases associated with abnormal protein aggregates. The patent contains 6 claims and was granted March 31, 2026, with original filing date November 27, 2020. No compliance deadlines are associated with this patent grant.